Who
Ashley Hall
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Structure Therapeutics; Chief Development Officer, OnKure Therapeutics; Chief Development Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $98K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 28 Jan 2021
- Last trade
- 19 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,706 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,073 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,073 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,706 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $102K4,836 at $20.99 | filing |
| 3 Mar 2026filed 5 Mar 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $102K4,836 at $20.99 | filing |
| 20 Nov 2025filed 5 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —237 at $0.00 | filing |
| 20 Nov 2025filed 5 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —237 at $0.00 | filing |
| 18 Sep 2025filed 22 Sep 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code F | $47K6,021 at $7.74 | filing |
| 20 May 2025filed 5 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225 at $0.00 | filing |
| 20 May 2025filed 5 Mar 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225 at $0.00 | filing |
| 15 Mar 2025filed 18 Mar 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —124,032 at $0.00 | filing |
| 15 Mar 2025filed 18 Mar 2025 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —51,048 at $0.00 | filing |
| 18 Sep 2024filed 20 Sep 2024 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,890 at $0.00 | filing |
| 18 Sep 2024filed 20 Sep 2024 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code A | —67,290 at $0.00 | filing |
| 28 Aug 2023filed 29 Aug 2023 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,625 at $0.00 | filing |
| 28 Aug 2023filed 29 Aug 2023 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Code M | $28K15,625 at $1.80 | filing |
| 28 Aug 2023filed 29 Aug 2023 | OKUR OnKure TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K15,625 at $6.28 | filing |
| 9 Dec 2022filed 13 Dec 2022 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 12 Nov 2021filed 15 Nov 2021 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.